Last updated on August 2018

Safety and Efficacy of Blinatumomab in Subjects With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma

Brief description of study

A phase 2, multicenter, open-label, single arm clinical trial in adult subjects with newly diagnosed aggressive high-risk DLBCL.

Detailed Study Description

The safety profile of blinatumomab after frontline R-chemotherapy, consisting of either R-CHOP (14 or 21) or R-DA-EPOCH or R-CHOEP, will be determined. The study will consist of a screening period of up to 14 days, a standard of care (SOC) R-chemotherapy run-in period of approximately 21 weeks, a 12 to 16 week blinatumomab treatment period, a 30-day safety follow-up visit, and a long-term follow-up period that begins after the safety follow-up visit is completed until 1 year from the first dose blinatumomab.

Clinical Study Identifier: NCT03023878

Contact Investigators or Research Sites near you

Start Over

Amgen Call Center

Research Site
Sault Ste. Marie, ON Canada